Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Athira Pharma Inc
(NQ:
ATHA
)
3.320
+0.210 (+6.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Athira Pharma Inc
< Previous
1
2
3
Next >
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
August 01, 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
May 15, 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
March 27, 2024
Via
Benzinga
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
January 02, 2024
The Dow Jones index closed lower by around 20 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
September 21, 2023
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
Via
Talk Markets
Athira Outlines Possible Comeback For Alzheimer's Candidate
September 06, 2022
Via
Benzinga
Athira Pharma: Q2 Earnings Insights
August 15, 2022
Athira Pharma (NASDAQ:ATHA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
4 Analysts Have This to Say About Athira Pharma
June 23, 2022
Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter:
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 12, 2023
Via
Benzinga
Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
June 07, 2023
The Dow Jones closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
$1.7M Bet On Glatfelter? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
April 03, 2023
The Dow Jones closed higher by more than 400 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
4 Penny Stocks Insiders Are Buying: Athira Pharma, Great Elm Group And More
January 03, 2023
US stocks recorded losses for 2022. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's...
Via
Benzinga
Beachbody, Athira Pharma And This Penny Stock Insiders Are Aggressively Buying
December 07, 2022
The Dow Jones closed lower by nearly 350 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Athira Pharma Shares Fall To 52-Week Low - Read Why
June 22, 2022
Via
Benzinga
Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying
November 18, 2022
US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
July 07, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
July 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
June 23, 2022
Upgrades
Via
Benzinga
10 Biggest Price Target Changes For Thursday: Alcoa, Travelers And More
June 23, 2022
Morgan Stanley cut Westinghouse Air Brake Technologies Corporation (NYSE: WAB) price target from $113 to $94. Westinghouse Air Brake Technologies shares fell 1.7% to $82.36 in pre-market trading.
Via
Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
June 23, 2022
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Via
Benzinga
Dow Jumps 150 Points; Ocean Bio-Chem Shares Spike Higher
June 22, 2022
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday.
Via
Benzinga
Stocks Quietly Higher as Market Attempts to Extend Rally
June 22, 2022
Stocks are modestly higher at midday.
Via
Talk Markets
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
June 22, 2022
U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 30 points on Wednesday.
Via
Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
June 22, 2022
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
Via
Benzinga
Exela Technologies (XELA) Stock Soars After Securing $136 Million Contract
June 22, 2022
Exela Technologies (XELA) stock is taking off on Wednesday after gaining a new $136 million customer contract that lasts for three years.
Via
InvestorPlace
Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results
June 22, 2022
Athira Pharma (ATHA) stock is plummeting on Wednesday following the outcome of a Phase 2 clinical trial of fosgonimeton.
Via
InvestorPlace
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
June 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Why Athira Pharma Stock Is Plunging
June 22, 2022
Athira Pharma Inc (NASDAQ: ATHA) shares are falling Wednesday after the company announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2022
April 21, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
May 10, 2022
Upgrades
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.